We are live on
!
Find out more
BSA
Braun Stacey Associates Portfolio holdings
AUM
$3.01B
1-Year Est. Return
47.79%
This Fund
S&P 500
This Quarter
Est. Return
+2.93%
1 Year Est. Return
+47.79%
3 Year Est. Return
+184.24%
5 Year Est. Return
+273.21%
10 Year Est. Return
+1,255.9%
AUM
$3.01B
AUM Growth
-$77.5M
(-2.5%)
Cap. Flow
-$45.6M
Cap. Flow
% of AUM
-1.52%
Top 10 Holdings %
Top 10 Hldgs %
32.99%
Holding
119
New
6
Increased
40
Reduced
57
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$28.4M |
| 2 |
Teledyne Technologies
TDY
|
+$17.1M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$14.5M |
| 4 |
IQVIA
IQV
|
+$13.6M |
| 5 |
Ryder
R
|
+$12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$25.9M |
| 2 |
ServiceNow
NOW
|
+$22.6M |
| 3 |
Boston Scientific
BSX
|
+$12.1M |
| 4 |
Micron Technology
MU
|
+$11.7M |
| 5 |
Western Digital
WDC
|
+$9.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.15% |
| 2 | Financials | 13.03% |
| 3 | Communication Services | 10.89% |
| 4 | Industrials | 10.55% |
| 5 | Healthcare | 9.34% |
Similar funds
CI
BGDI
ROTUOC
VVP
KIA
PCM
TAM
Braun Stacey Associates's Q1 2026 Portfolio in Review
As of Q1 2026, Braun Stacey Associates held 119 positions worth $3.01B, down 2.5% from $3.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Braun Stacey Associates's Q1 2026 filing shows 6 new, 40 increased, 57 reduced and 7 closed positions. Its largest new stake was Merck: 246,022 shares worth $29.6M. The largest sale was Neurocrine Biosciences, an estimated $25.9M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Financials and Communication Services.
- Braun Stacey Associates's largest Q1 2026 buy was Merck: 246,022 shares worth $29.6M.
- Braun Stacey Associates added most to Ascendis Pharma A/S in Q1 2026, an estimated $2.67M increase.
- Braun Stacey Associates's biggest Q1 2026 reduction was Boston Scientific, cutting an estimated $12.1M.
- Braun Stacey Associates fully exited Neurocrine Biosciences in Q1 2026, selling an estimated $25.9M.
- Braun Stacey Associates's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2026.
- Braun Stacey Associates opened 6 new positions and closed 7 in Q1 2026.
- Braun Stacey Associates's portfolio value fell 2.5% quarter-over-quarter to $3.01B.
Based on Braun Stacey Associates's 13F filing for Q1 2026, filed 22 Apr 2026.